Detalhe da pesquisa
1.
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
ESMO Open
; 1(4): e000068, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27843625